Mengyao Shi

Dr. Mengyao Shi

School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
Mengyao ShiMengyao Shi
Mengyao Shi
JHJiang He
Jiang He
CLChangwei Li
Changwei Li
XLXiangfeng Lu
Xiangfeng Lu
WHWilliam J. He
William J. He
TKTanika Kelly
Tanika Kelly

1 August 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
TKTanika Kelly
Tanika Kelly
XSXiao Sun
Xiao Sun
KHKaren Y. He
Karen Y. He
MBMichael Brown
Michael Brown
STSarah A. Gagliano Taliun
Sarah A. Gagliano Taliun
TCThe Samoan Obesity, Lifestyle, and Genetic Adaptations Study (OLaGA) Group,‡ NHLBI Trans-Omics for Precision Medicine TOPMed) Consortium
The Samoan Obesity, Lifestyle, and Genetic Adaptations Study (OLaGA) Group,‡ NHLBI Trans-Omics for Precision Medicine TOPMed) Consortium
Background: The availability of whole-genome sequencing data in large studies has enabled the assessment of coding and noncoding variants across the allele frequency spectrum for their associations with blood pressure. Methods: We conducted a multiancestry whole-genome sequencing analysis of blood pressure among 51 456 Trans-Omics for Precision Medicine and Centers for Common Disease Genomics program participants (stage-1). Stage-2 analyses leveraged array data from UK Biobank (N=383 145), Million Veteran Program (N=318 891), and Reasons for Geographic and Racial Differences in Stroke (N=10 643) participants, along with whole-exome sequencing data from UK Biobank (N=199 631) participants. Results: Two blood pressure signals achieved genome-wide significance in meta-analyses of stage-1 and stage-2 single variant findings ( P <5×10 -8 ). Among them, a rare intergenic variant at novel locus, LOC100506274 , was associated with lower systolic blood pressure in stage-1 (beta [SE]=−32.6 [6.0]; P =4.99×10 -8 ) but not stage-2 analysis ( P =0.11). Furthermore, a novel common variant at the known INSR locus was suggestively associated with diastolic blood pressure in stage-1 (beta [SE]=−0.36 [0.07]; P =4.18×10 -7 ) and attained genome-wide significance in stage-2 (beta [SE]=−0.29 [0.03]; P =7.28×10 -23 ). Nineteen additional signals suggestively associated with blood pressure in meta-analysis of single and aggregate rare variant findings ( P <1×10 -6 and P <1×10 -4 , respectively). Discussion: We report one promising but unconfirmed rare variant for blood pressure and, more importantly, contribute insights for future blood pressure sequencing studies. Our findings suggest promise of aggregate analyses to complement single variant analysis strategies and the need for larger, diverse samples, and family studies to enable robust rare variant identification.

18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
FLFanghua Liu
Fanghua Liu
PYPinni Yang
Pinni Yang
YWYinan Wang
Yinan Wang
Mengyao ShiMengyao Shi
Mengyao Shi
RWRuirui Wang
Ruirui Wang
JHJiang He
Jiang He
Background: We examined whether the relationship between baseline platelet count and clinical outcomes is modulated by HS‐CRP (high‐sensitivity C‐reactive protein) in patients with ischemic stroke. Methods and Results: A total of 3267 patients with ischemic stroke were included in the analysis. The primary outcome was a combination of death and major disability at 1 year after ischemic stroke. Secondary outcomes included major disability, death, vascular events, composite outcome of vascular events or death, and an ordered 7‐level categorical score of the modified Rankin Scale at 1 year. Multivariate logistic regression and Cox proportional hazards regression models were used to assess the association between the baseline platelet count and clinical outcomes stratified by HS‐CRP levels when appropriate. There was an interaction effect of platelet count and HS‐CRP on the adverse clinical outcomes after ischemic stroke (all P interaction <0.05). The elevated platelet count was significantly associated with the primary outcome (odds ratio [OR], 3.14 [95% CI, 1.77–5.58]), major disability (OR, 2.07 [95% CI, 1.15–3.71]), death (hazard ratio [HR], 2.75 [95% CI, 1.31–5.79]), and composite outcome of vascular events or death (HR, 2.57 [95% CI, 1.38–4.87]) among patients with high HS‐CRP levels (all P trend <0.05). Conclusions: The HS‐CRP levels had a modifying effect on the association between platelet count and clinical outcomes in patients with ischemic stroke. Elevated platelet count was significantly associated with adverse clinical outcomes in patients with ischemic stroke with high HS‐CRP levels, but not in those with low HS‐CRP levels. These findings suggest that strategies for anti‐inflammatory and antiplatelet therapy should be developed according to the results of both platelet and HS‐CRP testing.

24 October 2023 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
QXQingyun Xu
Qingyun Xu
YJYiming Jia
Yiming Jia
YWYi Wang
Yi Wang
PYPinni Yang
Pinni Yang
LSLulu Sun
Lulu Sun
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu

1 October 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
RWRuirui Wang
Ruirui Wang
YLYang Liu
Yang Liu
PYPinni Yang
Pinni Yang
Zhengbao ZhuZhengbao Zhu
Zhengbao Zhu
Mengyao ShiMengyao Shi
Mengyao Shi
JHJiang He
Jiang He
BACKGROUND: Increased blood pressure (BP) variability is positively associated with the risks of cerebral small-vessel disease, cardiovascular events and death. However, no large clinical trials have been published to demonstrate the effect of BP fluctuations during hospitalization on clinical outcomes after ischemic stroke. METHODS: A total of 3972 patients with acute ischemic stroke from 26 participating hospitals were included in this study, and BP fluctuations were calculated using BP data collected during the hospitalization. The primary outcome was composite outcome of death or major disability (modified Rankin Scale score ≥3) within 3 months and secondary outcomes included death, vascular events, and composite outcomes (death or vascular events). RESULTS: Compared with the lowest quartile of systolic BP fluctuations, the adjusted odds ratio associated with the highest quartile was 1.33 ([95% CI, 1.05–1.68]; P trend =0.011) for primary outcome; the adjusted hazard ratios were 2.89 ([95% CI, 1.58–5.32]; P trend <0.001) for death, 1.48 ([95% CI, 0.83–2.65]; P trend =0.071) for vascular events, and 2.06 ([95% CI, 1.32–3.23]; P trend <0.001) for composite outcome. Similar results were found for diastolic BP. Multivariable adjusted restricted cubic spline analysis showed a linear relationship between systolic BP fluctuations and the primary outcome ( P for linearity=0.0009). CONCLUSIONS: Larger BP fluctuations during hospitalization were associated with an increased risk of adverse outcomes at 3 months after ischemic stroke onset, independent of mean BP. These findings suggested that BP fluctuation should be a risk factor of adverse outcomes after ischemic stroke, which provided a new insight for BP management strategy.

13 November 2019 in Metabolomics
Verified
Journal Article
Open access
PDF file
JNJovia L. Nierenberg
Jovia L. Nierenberg
JHJiang He
Jiang He
Changwei LiChangwei Li
Changwei Li
XGXiaoying Gu
Xiaoying Gu
Mengyao ShiMengyao Shi
Mengyao Shi
TKTanika Kelly
Tanika Kelly
Introduction Chronic kidney disease (CKD) is a major public health challenge given its high global prevalence and associated risks of cardiovascular disease and progression to end stage renal disease. Although it is known that numerous metabolic changes occur in CKD patients, identifying novel metabolite associations with kidney function may enhance our understanding of the physiologic pathways relating to CKD. Objectives The objective of this study was to elucidate novel metabolite associations with kidney function among participants of two community-based cohorts with carefully ascertained metabolomics, kidney function, and covariate data. Methods Untargeted ultrahigh-performance liquid chromatography–tandem mass spectrometry was used to detect and quantify blood metabolites. We used multivariate adjusted linear regression to examine associations between single metabolites and creatinine-based estimated glomerular filtration rate (eGFRcr) among 1243 Bogalusa Heart Study (BHS) participants (median eGFRcr: 94.4, 5th–95th percentile: 66.0–119.6 mL/min/1.73 m2). Replication, determined by statistical significance and consistent effect direction, was tested using gold standard measured glomerular filtration rate (mGFR) among 260 Multi-Ethnic Study of Atherosclerosis (MESA) participants (median mGFR: 72.0, 5th–95th percentile: 43.5–105.0 mL/min/1.73 m2). All analyses used Bonferroni-corrected alpha thresholds. Results Fifty-one novel metabolite associations with kidney function were identified, including 12 from previously unrelated sub-pathways: N6-carboxymethyllysine, gulonate, quinolinate, gamma-CEHC-glucuronide, retinol, methylmalonate, 3-hydroxy-3-methylglutarate, 3-aminoisobutyrate, N-methylpipecolate, hydroquinone sulfate, and glycine conjugates of C10H12O2 and C10H14O2(1). Significant metabolites were generally inversely associated with kidney function and smaller in mass-to-charge ratio than non-significant metabolites. Conclusion The 51 novel metabolites identified may serve as early, clinically relevant, kidney function biomarkers.